These effects may be highly important aspects of the proposed neuroprotective activity of fingolimod in AD, suggesting its influence in the very early stages of the neurodegenerative processes (Fig. 7) in addition to the previously published restoration of BCL2 expression at later stages. This evidence concerns the gene BCL2 and Alzheimer disease.